Intraperitoneal Chemotherapy for Advanced Ovarian and Peritoneal Cancers in Patients Following Interval Debulking Surgery or Primary Cytoreductive Surgery: Tom Baker Cancer Centre Experience From 2006 to 2009

Journal of Obstetrics and Gynaecology Canada

Volumn 32, Issue 3, 2010, Pages 263-269

  Nelson, Gregory ^a   Lucero, Carlos Aspe ^a   Chu, Pamela ^a   Nation, Jill ^a   Ghatage, Prafull ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Interval debulking surgery; Intraperitoneal chemotherapy; Ovarian cancer; Recurrence

Indexed keywords

CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CATHETER INFECTION; CELLULITIS; CONSTIPATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FISTULA; HUMAN; HYPOMAGNESEMIA; INTERMETHOD COMPARISON; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MEDICAL DEVICE COMPLICATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PERITONEAL CATHETER; PERITONEAL VAGINAL FISTULA; PERITONEUM CANCER; PORT SITE LEAKING; RETROSPECTIVE STUDY; TINNITUS; TREATMENT OUTCOME; ADJUVANT THERAPY; INFUSION; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77954896484     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)34453-X     Document Type: Article

References (16)

1. United States National Institutes of Health. Clinical advisory: NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer. Available at: http://www.nlm.nih.gov/databases/alerts/ovarian_ip_chemo.html. Access May 15, 2009.
2. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996, 335:1950-1955.
3. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:1001-1004.
4. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-35.
5. Naumann R., Sukumvanich P., Edwards R. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. Gynecol Oncol 2009, 114(1):37-41.
6. Tiersten A.D., Liu P.Y., Smith H.O., Wilczynski S.P., Robinson W.R., Markman M., et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol 2009, 112:444-449.
7. Vergote I, Trope CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, et al. EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer. Plenary presentation at the 12th biennial meeting International Gynecologic Cancer Society IGCS, Bangkok, Thailand, October 25-28, 2008 (abs.).
8. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Available at:. Accessed June 1, 2009. http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
9. Chin S.N., Pinto V., Rosen B., Oza A., Dodge J., Murphy J., et al. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecol Oncol 2009, 112:450-454.
10. Berry E., Matthews K.S., Singh D.K., Buttin B.M., Lurain J.R., Alvarez R.D., et al. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol 2009, 113:63-67.
11. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006, 100:27-32.
12. Kaye S.B., Paul J., Cassidy J., Lewis C.R., Duncan I.D., Gordon H.K., et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996, 14:2113-2119.
13. Conte P.F., Bruzzone M., Carnino F., Gadducci A., Algeri R., Bellini A., et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ouest. J Clin Oncol 1996, 14:351-356.
14. McGuire W.P., Hoskins W.J., Brady M.F., Homesley H.D., Creasman W.T., Berman M.L., et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995, 13:1589-1599.
15. Walker J.L. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol 2009, 112:439-440.
16. An NCIC (National Cancer Institute of Canada) CTG led GCIG Study. A phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy. Presented at the NCIC spring meeting, April 2009.